↓ Skip to main content

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

Overview of attention for article published in Frontiers in immunology, November 2021
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
9 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
Published in
Frontiers in immunology, November 2021
DOI 10.3389/fimmu.2021.753890
Pubmed ID
Authors

Fabio Guolo, Paola Minetto, Silvia Pesce, Filippo Ballerini, Marino Clavio, Michele Cea, Michela Frello, Matteo Garibotto, Marco Greppi, Matteo Bozzo, Maurizio Miglino, Monica Passannante, Riccardo Marcolin, Elisabetta Tedone, Nicoletta Colombo, Rosa Mangerini, Alessandra Bo, Maria Rosaria Ruzzenenti, Paolo Carlier, Alberto Serio, Silvia Luchetti, Alida Dominietto, Riccardo Varaldo, Simona Candiani, Vanessa Agostini, Jean Louis Ravetti, Genny Del Zotto, Emanuela Marcenaro, Roberto Massimo Lemoli

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 9%
Student > Ph. D. Student 3 9%
Other 2 6%
Student > Bachelor 2 6%
Lecturer > Senior Lecturer 1 3%
Other 4 13%
Unknown 17 53%
Readers by discipline Count As %
Medicine and Dentistry 5 16%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Biochemistry, Genetics and Molecular Biology 2 6%
Nursing and Health Professions 2 6%
Engineering 2 6%
Other 3 9%
Unknown 16 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2021.
All research outputs
#7,279,010
of 26,178,577 outputs
Outputs from Frontiers in immunology
#7,999
of 32,859 outputs
Outputs of similar age
#135,485
of 448,572 outputs
Outputs of similar age from Frontiers in immunology
#423
of 1,532 outputs
Altmetric has tracked 26,178,577 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 32,859 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,572 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 1,532 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.